WJ Sandborn, BG Feagan, S Stoinov, PJ … - The New England journal of medicine, 2007 - nejm.highwire.org From the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
(WJS); the University of Western Ontario, London, ON, Canada (BGF); Clinic of
Gastroenterology, Multiprofile Hospitals for Active Treatment Queen Ioanna, ... Cited by 177 - Related articles - BL Direct - All 6 versions
G Van Assche, C Magdelaine–Beuzelin, G D' … - Gastroenterology, 2008 - Elsevier Background & Aims: The benefit to risk ratio of concomitant immunosuppressives
with scheduled infliximab (IFX) maintenance therapy for Crohn's disease is an
issue of debate. We aimed to study the influence of immunosuppressives ... Cited by 61 - Related articles - All 4 versions
- ►mayoclinicproceedings.com S Tsiodras, G Samonis, DT Boumpas, DP … - Mayo Clinic Proceedings, 2008 - mayoclinproc.highwire.org Tumor necrosis factor α (TNF-α) blockade has emerged as a useful therapy for
collagen vascular diseases or graft-vs-host disease. Fungal infections
complicating such therapy have been reported sporadically. MEDLINE and ... Cited by 32 - Related articles - BL Direct - All 8 versions
- ►upenn.edu [PDF] WJ Sandborn, BG Feagan, RN Fedorak, E … - Gastroenterology, 2008 - Elsevier Background & Aims: Interleukin-12 and interleukin-23 are inflammatory cytokines
implicated in Crohn's disease pathophysiology. Ustekinumab is a monoclonal
antibody against the p40 subunit of interleukin-12/23. Methods: We ... Cited by 29 - Related articles - All 5 versions
- ►prsjournal.net J Panes, F Gomollon, C Taxonera, J Hinojosa, … - Drugs, 2007 - ingentaconnect.com 1 Department of Gastroenterology, Hospital Clinic, Barcelona, Spain 2 Servicio
de Aparato Digestivo, Hospital Clinico Universitario, Zaragoza, Spain 3
Department of Gastroenterology, Hospital Clinico San Carlos, Madrid, Spain ... Cited by 22 - Related articles - BL Direct - All 7 versions
P Michetti, C Mottet, P Juillerat, V Pittet, C … - Digestion, 2007 - content.karger.com Patients with moderate-to-severe disease and patients with steroid-refractory or
steroid-dependent disease differ in their management, as the latter two groups
usually involve patients whose condition is less acute. Systemic ... Cited by 18 - Related articles - BL Direct - All 6 versions
L Peyrin-Biroulet, P Desreumaux, WJ … - The Lancet, 2008 - Elsevier In the past few years, antagonists of tumour necrosis factor have resulted in
unforetold therapeutic benefits in Crohn's disease, but the magnitude and
duration of responses are variable. New agents are therefore needed. Their ... Cited by 19 - Related articles - All 40 versions
P Rutgeerts, S Vermeire, G Van Assche - Gastroenterology, 2009 - Elsevier Crohn's disease and ulcerative colitis are chronic disabling inflammatory bowel
diseases (IBDs). Although the causes of IBD are unknown, defects in innate and
adaptive immune pathways have been identified and biological therapies that ... Cited by 17 - Related articles - All 28 versions
GT Ho, L Smith, S Aitken, HM Lee, T Ting, J … - Alimentary Pharmacology and Therapeutics, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 15 - Related articles - BL Direct - All 7 versions
- ►nih.gov JF Colombel, DA Schwartz, WJ Sandborn, MA … - British Medical Journal, 2009 - gut.bmj.com Online First articles must include the digital object identifier (DOIs) and date
of initial publication. establish publication priority; they are indexed by
PubMed from initial publication. Citations to may be posted when available ... Cited by 15 - Related articles - All 6 versions
